Avidity Biosciences Inc (RNA)’s stock has witnessed a price hike of 1.64% from the previous close with its current price standing at $40.88. Its current price is -27.00% under its 52-week high of $56.00 and 90.04% more than its 52-week low of $21.51.
Additionally, it is important to take into account RNA stock ratios, including its price-to-sales ratio, which is 547.28 for the last tewlve months.RNA’s price to book ratio for the most recent quarter was 4.14, resulting in an 4.96 price to cash per share for the period.
How does Avidity Biosciences Inc (RNA) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
Avidity Biosciences Inc (RNA): Earnings History
If we examine Avidity Biosciences Inc’s recent earnings history, in the last quarter ended on 6/30/2025, it posted adjusted earnings per share of -$1.21, beating the consensus of -$0.96. In other words, it beat the consensus by -$0.25, resulting in a -26.33% surprise. In the 3 months period before the previous quarter which was closed on 6/30/2025, the stock recorded adjusted earnings per share of -$1.21 in contrast with the Outlook of -$0.96. That was a difference of -$0.25 and a surprise of -26.33%.
Avidity Biosciences Inc (NASDAQ: RNA) Ownership Details
I will give a breakdown of the key shareholders in Avidity Biosciences Inc (RNA). Recent figures show that the company’s insiders hold 4.53% of shares. A total of 306 institutional investors hold shares in the company, making 101.77% of its stock and 106.60% of its float.
Jul 31, 2025, it was reported that the Company’s largest institutional holder is Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund holding total of 3.99 shares that make 3.10% of the company’s total number of shares and are currently priced at 163.04 million.
The securities firm T. Rowe Price New Horizons Fund, Inc. holds 3.95 shares of RNA, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 3.07%, and the holding percentage of shares is valued at 161.38 million.
